Needham analyst David Saxon has maintained their neutral stance on STAA stock, giving a Hold rating yesterday.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

David Saxon has given his Hold rating due to a combination of factors tied to Staar Surgical’s near-term outlook and risk profile. On the one hand, the company’s preliminary second-quarter revenue guide slightly above consensus highlights solid demand in key markets such as broader Asia-Pacific, including China, and the Americas, indicating that core growth drivers remain intact.

At the same time, Saxon flags meaningful uncertainties that temper the upside case, notably geopolitical-related softness in parts of EMEA, ongoing operational issues from the ERP rollout, and the risk that macroeconomic pressures could spread to additional regions in the second half of 2026. These crosscurrents leave the balance of risks—between continued strength in China and the Americas and potential broader macro weakness—too finely poised to justify a more aggressive rating at this stage, leading him to maintain a Hold while awaiting full 2Q26 results for clearer visibility.

According to TipRanks, Saxon is a 2-star analyst with an average return of 0.0% and a 35.43% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Glaukos, Staar Surgical, and Irhythm Technologies.